Skip to Main Content

About Janssen Research & Development, LLC

Janssen Research & Development provides research and development support for the pharmaceutical business units of parent company Johnson & Johnson (J&J). The company divides its main research processes into central nervous system and internal medicine; biotech, immunology, and oncology (in concert with fellow J&J subsidiary Janssen Biotech); and virology (with another J&J unit, Tibotec). The subsidiary -- which represents the largest segment of J&J's pharmaceutical R&D -- also does research in collaboration with other pharmaceutical organizations and biotech researchers.


Janssen Research & Development focuses on developing treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases, and vaccines, neuroscience, and oncology. Many of the medicines researched and developed by Janssen Research & Development are now big global sellers for parent company J&J. Some of the top products are Procrit for anemia, Stelara for psoriasis, Prezista for HIV, and Concerta for attention deficit hyperactivity disorder (ADHD).

Geographic Reach

Janssen Research & Development operates in more than 150 nations; it has research hubs around the globe, including locations in Australia, Belgium, the Czech Republic, China, Denmark, Finland, France, Germany, India, Ireland, Italy, Japan, the Netherlands, New Zealand, Russia, Singapore, Spain, Switzerland, the UK, and the US (California, New Jersey, and Pennsylvania). Its central nervous system and internal medicine unit works on psychiatric, neurology, pain, infection, cardiovascular, and metabolic disease targets, primarily at the La Jolla, California, research center. Its virology division works with Tibotec on HIV and tuberculosis treatments from facilities in Belgium, Ireland, and the US.

Financial Performance

Janssen Research & Development is part of Johnson & Johnson's Pharmaceuticals business segment, which contributes about 45% of its overall annual revenues. In 2016, the segment's revenue grew 7% to $33.5 billion.


Janssen Research & Development's strategy is to identify the unmet medical needs and match them with science (organically or with the help of partners) to find effective treatments for patients. Its current development pipeline, which it hopes will produce tomorrow's blockbusters, includes potential treatments for diabetes, leukemia, ovarian cancer, HIV, and stroke prevention. The group also targets global public health issues to improve care around the world. These efforts include the development of maternal and child care programs as well as HIV and other vaccines for developing markets.

The three pillars of Janssen Research & Development's latest strategy are disease prevention, disease intervention, and the microbiome. In terms of prevention, the team targets such areas as Alzheimer's, heart disease, cancer, and autoimmune diseases. Disease prevention research utilizes data from genetics, the environment, and other factors to detect such ailments as Type 1 diabetes and cancer before patients become ill. Activities related to the microbiome, a fast-growing field, seek to better understand how populations of bacteria impact disease and/or improve overall health.

Overall, J&J spends more than $6.5 billion on pharmaceutical research each year. Once the products are approved by regulators, they are passed along to other J&J units for commercialization.

Janssen Research & Development, LLC

920 US Highway 202
Raritan, NJ 08869-1420
Phone: 1 (908) 704-4000

Firm Stats

Employer Type: Privately Owned
Global Head: William N. Hait
Head, Neuroscience Therapeutic Area: Husseini K. Manji
Chief Scientific Officer: Paulus Stoffels
Employees (This Location): 1,800
Employees (All Locations): 4,963

Major Office Locations

Raritan, NJ

Other Locations

San Diego, CA
New Providence, NJ
Spring House, PA